Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Appian

Start price
Target price
Perf. (%)
€33.32
02.03.24
€45.00
02.03.25
-0.09%
16.03.24

Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Fair valuation
buy
Aixtron SE

Start price
Target price
Perf. (%)
€28.18
02.03.24
€30.00
02.03.25
-9.30%
16.03.24

Could be worthwhile Investment >10% per year
buy
Green Hydrogen Systems A/S

Start price
Target price
Perf. (%)
€1.22
02.03.24
€1.00
02.03.25
-
03.03.24

Market Leader or Top 3
Very small cyclical dependencies
Well known brand
Very Future proof/growth oriented business model
Bigbear.ai Holdings Inc.

Start price
Target price
Perf. (%)
€3.62
28.02.24
-
28.02.25
-3.31%
02.03.24

Risky Investment
buy
Progress-Werk Oberkirch

Start price
Target price
Perf. (%)
€29.60
27.02.24
-
27.02.25
-2.70%
18.03.24

SynBiotic SE

Start price
Target price
Perf. (%)
€13.10
23.02.24
-
23.02.25
-17.94%
27.02.24

buy
Super Micro Computer

Start price
Target price
Perf. (%)
€779.80
22.02.24
€1,000.00
22.02.25
19.42%
02.03.24

Known brand
Could be worthwhile Investment >10% per year
Higher EBIT margin than peer group
Low dividend yield expected
Sangamo Therapeutics Inc.

Start price
Target price
Perf. (%)
€1.19
22.02.24
-
22.02.25
-10.80%
02.03.24

Nicheplayer
Risky Investment
buy
H&R GmbH & Co. KGaA

Start price
Target price
Perf. (%)
€5.20
22.02.24
€5.00
22.02.25
-5.00%
02.03.24

Good culture
Revenue growth >5% per year expected
Capable Management
Little innovation
buy
Novagold Resources

Start price
Target price
Perf. (%)
€2.18
20.02.24
-
20.02.27
37.06%
02.04.24

Could be worthwhile Investment >10% per year
Green Hydrogen Systems A/S

Start price
Target price
Perf. (%)
€0.73
19.02.24
€0.67
19.02.25
61.81%
02.03.24

Market Leader or Top 3
Very small cyclical dependencies
Well known brand
Very Future proof/growth oriented business model
Minerva Neurosciences Inc.

Start price
Target price
Perf. (%)
€7.79
19.02.24
€6.00
16.05.26
-69.17%
03.03.24

Could be very worthwhile Investment >20% year
buy
Ardelyx Inc.

Start price
Target price
Perf. (%)
€8.30
19.02.24
-
19.02.25
2.41%
03.03.24

Could be worthwhile Investment >10% per year
Sangamo Therapeutics Inc.

Start price
Target price
Perf. (%)
€1.40
19.02.24
-
19.02.25
-24.14%
04.03.24

Risky Investment
buy
Gritstone Oncology Inc

Start price
Target price
Perf. (%)
€2.01
18.02.24
-
18.02.25
-2.59%
03.03.24

Risky Investment
buy
Cegedim

Start price
Target price
Perf. (%)
€16.78
17.02.24
-
17.02.25
-4.41%
02.03.24

Could be worthwhile Investment >10% per year
buy
2CRSI S.A.

Start price
Target price
Perf. (%)
€5.14
17.02.24
-
17.02.25
-14.98%
02.03.24

Could be worthwhile Investment >10% per year
buy
Plug Power Inc.

Start price
Target price
Perf. (%)
€3.59
17.02.24
€4.00
17.02.25
3.06%
09.03.24

Good rating
Revenue growth > 30% per year expected
Higher EBIT margin than peer group
Fair valuation
buy
Amadeus FiRe AG

Start price
Target price
Perf. (%)
€111.60
17.02.24
€150.00
17.02.25
-2.33%
02.03.24

buy
Aurinia Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€5.50
15.02.24
-
15.02.25
-3.09%
17.02.24

Risky Investment
buy
Motor Oil Hellas

Start price
Target price
Perf. (%)
€27.20
09.02.24
-
09.02.25
-2.57%
17.02.24

Glatfelter Corp.

Start price
Target price
Perf. (%)
€2.24
07.02.24
€1.00
07.02.25
-10.69%
17.02.24

Good culture
No Innovation
Risky Investment
Below average Management
buy
Uranium Energy Corp

Start price
Target price
Perf. (%)
€7.50
06.02.24
-
06.02.25
-5.31%
15.02.24

buy
Karyopharm Therapeutics Inc.

Start price
Target price
Perf. (%)
€1.35
05.02.24
-
05.02.25
29.34%
06.02.24

Could be worthwhile Investment >10% per year
Capable Management
Good culture
Few uniques
Coherus Bioscien.

Start price
Target price
Perf. (%)
€1.88
05.02.24
-
05.02.25
33.90%
17.02.24

Probably not worthwhile Investment
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
High valuation